We innovate in the fight against cancer because “standard” has never been good enough.
We are a genomic diagnostic company founded by a team of cancer biologists, urologic oncologists, and data scientists who came together with a common goal – to transform urologic cancer care through revolutionary genomics. Combining advances in next-generation sequencing and machine learning, our technology arms clinicians with insights that can help them better personalize their patients’ cancer care.
We are on the cusp of a new era of genomics in urology, and we are leading the way.
“Revolutionizing cancer care requires embracing the vast diversity of this disease to understand its root biologic cause. Our hope is that every person may have access to genomic data that improves the understanding of their unique cancer risk.”
Trevor Levin, Ph.D., Founder and CEO
Leadership
Trevor Levin
Ph.D., Founder, CEO
Trevor Levin is the Founder and Chief Executive Officer of Convergent Genomics. Dedicated to developing methods of diagnostic early detection and risk prognosis for cancer patients, he guides the company in leveraging the latest genomic technology to gain insights that will enable data-driven and personalized treatment choices. His technical background is complemented by his ambitious entrepreneurship and goal of translating laboratory discovery into viable products to help cancer patients.
Trevor completed his doctoral research in stem cell and cancer biology at Oregon Health & Science University (OHSU), where he was a NIH Kirschstein Research Program Awardee. He completed an entrepreneurial fellowship at OHSU’s esteemed Knight Cancer Institute (KCI) with Dr. Joe Gray, serial inventor of diagnostic technologies, including FISH. During this time, he was a lead investigator on commercialization awards from the OCTRI Biomedical Innovation Program and Business Oregon. He also co-founded the KCI’s Cancer Patient Advocacy program, where he connected cancer survivors and advocates with researchers to enhance patient-centric research. He founded Convergent in 2015 in partnership with OHSU and Illumina Accelerator. Trevor has led the development of Convergent’s technology platform and patent portfolio, secured financial support through strategic and equity investment, as well as securing highly competitive grants from the NCI’s Small Business Innovation Research program. In 2019 Convergent was selected as one of the top three companies in the US to receive a phase 2B SBIR investment from the NCI.
Trevor Levin
Ph.D., Founder, CEO
Iden Haddadzadeh
Chief Operating Officer
Iden Haddadzadeh is the Chief Operating Officer of Convergent Genomics, providing oversight of key company operations, administration, and policies. He works closely with the executive team to envision and execute the company’’s strategic plan and also collaborates with department heads to draft and implement company-wide initiatives and protocols that support day-to-day productivity. Excelling at anticipating obstacles in business operations, he proactively addresses potential issues to ensure the company’’s continued record of success in providing personalized care to cancer patients.
A passionate and competent operations executive, Iden has over 12 years of experience shaping innovative companies and leading biotech startups. His contributions to early-stage genomic startups have resulted in various company-owned patents, multiple peer-reviewed publications, two startup acquisitions, multiple fundraising rounds for three different startups, and successful product launches in healthcare. Iden joined Convergent Genomics’’s founding team as the first operations and business hire in 2017 and played an instrumental role in growing the team, raising funds, and building the infrastructure that translated great science into a commercial product. He holds an MBA from Pepperdine University with a concentration in entrepreneurship.
Iden Haddadzadeh
Chief Operating Officer
Dr. Brian Mazzarella
Chief Medical Officer
Dr. Brian Mazzarella is the Chief Medical Officer for Convergent Genomics. In addition to building and overseeing the company’s Medical Affairs team, he provides clinical perspectives on regulatory licensing, reporting, and commercialization and input into clinical trial development and execution. Applying his skills as a urologist and clinician to the company’s entrepreneurial culture and rapidly growing business, he finds motivation in working alongside colleagues who are translating innovative science into clear, measurable, and accessible clinical impact.
Dr. Mazzarella is a board-certified and practicing urologist. He is a Fellow of the American College of Surgeons. He is an experienced principal investigator and continues to lead urologic clinical research. Throughout his career as a urologist, he has been a leader in physician training, education, and the development of new products and technologies.
Dr. Mazzarella started his career helping those in need as a volunteer firefighter and EMT while completing his undergraduate degree.
Dr. Brian Mazzarella
Chief Medical Officer
Len Farris
Chief Commercial Officer
Len Farris is the Chief Commercial Officer at Convergent Genomics. As a key member of the executive team, he is focused on the strategic growth of the company through the development and execution of its plans and programs across the commercial organization – including sales, marketing, and market access. He is committed to translating the company’s scientific advances in genomics to clinical utility, integrating customer insights into commercial decisions, and developing teams that collaborate seamlessly with patients, providers, and practices.
Prior to joining Convergent Genomics, Len held management positions at Teleflex, Pentax Medical, OmniSonics, Boston Scientific, and Pfizer, with roles that included sales, marketing, clinical, field service, and R&D positions. He also holds patents on endoscopic visualization and cardiology catheters, has authored several articles on medical innovation, and served as an officer in the United States Air Force.
Len Farris
Chief Commercial Officer
Monica Ransom
Vice President of Clinical Affairs
Monica Ransom is Vice President of Clinical Affairs at Convergent Genomics, where she develops the overall clinical program strategy for products from early development to life cycle management and manages the execution of the clinical studies in early cancer detection. As a key leader in the organization, she provides counsel to its governing and oversight bodies, manages multiple clinical programs, and leads program teams to design and implement clinical studies to address patients’ needs and deliver on the company’s strategic vision.
With a thorough understanding of clinical trial design, execution, and operations and a comprehensive grasp of FDA regulations, Monica has over 20 years of experience that includes global clinical trials across drugs (phases I-IV), devices and diagnostics. Her career consists of 12 years of clinical operations leadership, and her work at Convergent Genomics is anchored in the gratification of knowing that the investment, rigor, and exceptional caliber of the company’s clinical trials ultimately benefit the lives of the cancer patients it serves.
Monica Ransom
Vice President of Clinical Affairs
Shane Carlson
Vice President of Sales
Shane Carlson is Vice President of Sales at Convergent Genomics and is a high-performing sales leader who uses a comprehensive, motivational approach to drive results. Responsible for building out and leading the commercial sales team for the launch of UroAmp, his approach centers around being ambitious and bold while promoting a culture of trust and compassion.
Inspired to make a positive difference in the world by impacting patients’ lives, Shane launched his career in pharmaceuticals and transitioned to the medical device industry, where he was promoted into roles of increasing responsibility and leading large sales teams. His extensive experience includes roles in the startup and early-stage space and managing his teams through acquisitions.
Shane Carlson
Vice President of Sales
Barbara Hamlington
Senior Director
of Medical Affairs
Barbara Hamlington is the Senior Director of Medical Affairs at Convergent Genomics and is focused on building brand awareness and product understanding by facilitating collaborations with leaders in the field and amplifying the impact of scientific output generated by the company’s data and science teams. An essential partner to the executive team, she collaborates with the Chief Medical Officer to build out the medical affairs organization at Convergent Genomics.
Having earned her BS in Neuroscience and MS in Genetic Counseling at the University of Michigan, Barbara has extensive research, teaching, and commercial experience in the field of clinical science. She is energized by the challenges and potential of introducing a new diagnostic tool into clinical practice and embraces the opportunity to build and strengthen connections both within Convergent Genomics and the industry at large to further advance patient care.
Barbara Hamlington
Senior Director of Medical Affairs
Kevin Phillips, Ph.D.
Director of Data Science
& Bioinformatics
Kevin Phillips is the Director of Data Science & Bioinformatics at Convergent Genomics, where he is dedicated to improving the lives of cancer patients by leveraging genomic data analyses to speed diagnoses, inform therapeutic strategies, and support disease monitoring. His commitment to continuous quality control, data validation procedures, and patient information protection is a driving force behind the company’s ability to intelligently and non-invasively personalize medical care for individuals, establishing it as an industry leader through advances in genomics and machine learning.
Joining Convergent Genomics in 2016, Kevin trained as a physicist before entering the field of cancer biology, in which he developed quantitative optical tools to elucidate the physical properties of cancer at the cellular level. His technical expertise is complemented by interests in both entrepreneurship and business development, with the goal of translating data analysis into viable tools for clinical diagnostics that directly benefit patients.
Kevin Phillips, Ph.D.
Director of Data Science
& Bioinformatics
Vincent Bicocca, Ph.D.
Director of Research & Development
Vincent Bicocca, Ph.D., is the Director of Research and Development at Convergent Genomics. He leads a team committed to personalizing medical care for cancer patients through the identification of disease-specific genomic information that speeds diagnoses, informs therapeutic strategies, and supports disease monitoring.
Dr. Bicocca obtained his Ph.D. from Oregon Health & Science University in the lab of Dr. Brian Druker, where he discovered the receptor tyrosine kinase ROR1 as a therapeutic target in B-cell malignancies. As a postdoctoral fellow of the National Cancer Institute, he developed NGS-based methods and tools to study epigenetic mechanisms and genome regulation in the lab of Dr. Eric Selker at the University of Oregon.
Vincent Bicocca, Ph.D.
Director of Research & Development
Melissa Vidamo
Director of Clinical Lab Operations
Melissa Vidamo is the Director of Clinical Lab Operations at Convergent Genomics, where she has spearheaded numerous initiatives to streamline processes and enhance efficiency while maintaining strict adherence to quality and safety standards. Her passion for improving patient outcomes is evidenced by her commitment to continuous innovation and drives her dedication to cancer diagnostics.
Spanning over 20 years in healthcare, Melissa’s career includes pivotal roles at some of the top institutions in the field, including UC San Diego, Kaiser Permanente, Illumina, and Guardant Health. She earned both her BS and MD degrees at Saint Louis University in the Philippines and has visited seven continents and more than 60 countries, lending her a unique understanding of the challenges facing healthcare systems around the world. This valuable global perspective and her commitment to patients have shaped her approach to improving quality of care and has established her as a respected leader in the industry.
Melissa Vidamo
Director of Clinical Lab Operations
Megan LaRosa
Director of Marketing
Megan LaRosa is the Director of Marketing at Convergent Genomics, overseeing the development and execution of robust go-to-market strategies, marketing plans and programs that support the company’s growth objectives and engage its target audiences. With over 10 years of experience in the healthcare industry, she is inspired by the opportunity to deliver advanced technologies to improve quality of life and outcomes for cancer patients.
Megan’s experience most recently includes a global marketing role at Draeger, where she was responsible for leading, developing, and managing the roll-out of international marketing plans for product launches and various campaign initiatives. She has also held various marketing positions at Teleflex and ZOLL Medical and has an MBA in Marketing and an MSM in Healthcare Administration.
Megan LaRosa
Director of Marketing
